Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
about
Emerging data on androgen receptor splice variants in prostate cancerFrom rabbit antibody repertoires to rabbit monoclonal antibodiesMolecular biomarkers to guide precision medicine in localized prostate cancer.Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.RNA splicing and splicing regulator changes in prostate cancer pathologyTherapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.Clinical relevance of androgen receptor alterations in prostate cancer.Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Non-invasive actionable biomarkers for metastatic prostate cancer.Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
P2860
Q28077830-26C4E7DA-7388-43CF-B845-709B5C2C06C6Q37739483-023D4D53-CD88-466C-9A2F-8A19EE7E4A31Q38668635-E48F850E-CE6B-46E5-A93B-0544157AF0BDQ38743584-2F289754-29E0-4E58-B682-1D583C5B782BQ38833356-CB53A76C-288B-45ED-A629-7631C76A3484Q38983790-7235816B-F324-4FAC-9B94-B8D09737C374Q39172297-8FCD31BA-E93E-4F0D-ABE1-E73663A1DF92Q39215035-DCFA99D9-1F71-4520-8062-2D75F45B77ACQ39223617-CAE7F4AC-1157-4369-8B04-4AA944A9A902Q39347702-0B213B7E-658B-431D-8CAD-5E7AFC7D2C99Q39612538-499671B2-7B80-4E40-8987-2ED9EB9D946AQ40423383-A773E7D3-F7B0-48B9-BE08-FFD6D853FEBAQ41167484-B96341CB-1BA6-4C9B-8CBA-E45ACD17D5D7Q41832140-47ABDB57-2209-4C67-9A7B-BACBA4F9A863Q42125180-9A10D2C2-3913-4ACC-AA3B-85ED8459A955Q42377108-0063F126-F4FE-4B71-9EDC-5371A1D8BA03Q42776456-63F72012-B171-4E4C-81BD-DC11AB194BC8Q46233223-9CB5B25F-A6B5-40AA-AC7E-CC0DFD9B6263Q47281377-6C172A44-844D-4251-85D4-56B58B56C27AQ47740995-9AB58256-7A6A-4D57-8BF2-99A415BA3CC5Q51465026-BA9845AF-7CE0-4DD4-B1F8-2439213072B8Q51789456-EA1A23EC-0E34-461B-96AB-781951262011Q52861100-F0D43529-5C08-4615-B525-DE0CA90D614F
P2860
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@en
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@nl
type
label
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@en
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@nl
prefLabel
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@en
Analytical Validation and Clin ...... ion-resistant Prostate Cancer.
@nl
P2093
P2860
P50
P1433
P1476
Analytical Validation and Clin ...... tion-resistant Prostate Cancer
@en
P2093
Daniel Nava Rodrigues
Ines Figueiredo
Johann S de Bono
Ruth Riisnaes
Shihua Sun
Stephen R Plymate
Zafeiris Zafeiriou
P2860
P304
P356
10.1016/J.EURURO.2016.03.049
P407
P577
2016-04-23T00:00:00Z